Rheumatology
M-A | Little benefit from viscosupplementation in knee osteoarthritis.
11 Jul, 2022 | 12:39h | UTCViscosupplementation for knee osteoarthritis: systematic review and meta-analysis – The BMJ
News Release: Scant evidence to recommend use of hyaluronic acid injections for knee osteoarthritis – BMJ Newsroom
Commentary: Common injections don’t help knee osteoarthritis more than placebo, large data review finds – STAT
Commentary on Twitter
New research finds that injections of hyaluronic acid to treat knee osteoarthritis make almost no difference to pain and might raise risk of adverse events https://t.co/G80BHoOgl3
— The BMJ (@bmj_latest) July 7, 2022
2022 ACR Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.
11 Jul, 2022 | 12:29h | UTCSee also: Guideline Summary (PDF)
Consensus Paper | Cardiovascular magnetic resonance in autoimmune rheumatic diseases.
11 Jul, 2022 | 12:26h | UTC
RCT | Ustekinumab does not improve outcomes in patients with systemic lupus erythematosus.
8 Jul, 2022 | 11:39h | UTC
RCT | Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy.
7 Jul, 2022 | 12:44h | UTC
Commentary on Twitter
SELECT-AXIS 2 trial – patients with #AS and inadequate response to #bDMARDs. #RCT of upadacitinb vs placebo 14 weeks:
Improved signs and symptoms of active AS and was well tolerated for 14 weeks of treatment in bDMARD-IR patients!https://t.co/Z7fuxiXMDb pic.twitter.com/kGZX9AsaVE— ARD & RMD Open (@ARD_BMJ) July 5, 2022
Post-hoc analysis | Can SGLT2 inhibitors reduce the risk of hyperuricemia and gout?
7 Jul, 2022 | 12:40h | UTC
Registry-based cohort study | Association between gout and cardiovascular outcomes in adults with no history of cardiovascular disease.
7 Jul, 2022 | 12:32h | UTC
Commentary on Twitter
Read now the latest research on the association between gout and #CardiovascularOutcomes.▶️ https://t.co/DV4BYXWAZI#BMJMedicine #CardivascularEvents #MedTwitter
Highlights below ⬇️ pic.twitter.com/lDc1Y2Vt0E— BMJMedicine (@BMJMedicine) July 5, 2022
RCT | Ozoralizumab vs. placebo in patients with active rheumatoid arthritis despite methotrexate therapy.
6 Jul, 2022 | 11:12h | UTCCommentary: Ozoralizumab shows promise in methotrexate-resistant RA – medwire News
Systematic Review | No evidence in support of arthroscopic partial meniscectomy in adults with degenerative and nonobstructive meniscal symptoms.
5 Jul, 2022 | 11:38h | UTCConsensus Guidance | Updated treatment recommendations for psoriatic arthritis.
4 Jul, 2022 | 12:31h | UTCGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 – Nature Reviews Rheumatology (if the link is paywalled, try this one in PMC Central)
See also (just published): Update on the Management of Pediatric Psoriasis: An Italian Consensus – Dermatology and Therapy
Related:
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs – Rheumatology
Spondyloarthritis in over 16s: diagnosis and management – NICE Updated Guideline
Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study.
4 Jul, 2022 | 12:24h | UTCRelated: The Global Burden of Musculoskeletal Pain—Where to From Here? – American Journal of Public Health
Review | Lowering and raising serum urate levels: off-label effects of commonly used medications.
4 Jul, 2022 | 12:10h | UTCEffectiveness of remote care interventions: a systematic review informing the 2022 EULAR Points to Consider for remote care in rheumatic and musculoskeletal diseases.
29 Jun, 2022 | 10:47h | UTCSee Guideline: 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases – Annals of Rheumatic Diseases
Drug treatment algorithm and recommendations for the management of rheumatoid arthritis.
28 Jun, 2022 | 11:05h | UTC
EULAR/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases.
24 Jun, 2022 | 11:17h | UTC
EULAR/ACR points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases.
24 Jun, 2022 | 11:23h | UTC
Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.
24 Jun, 2022 | 11:13h | UTC
M-A: Effect of different types of exercise in adult subjects with fibromyalgia.
24 Jun, 2022 | 10:52h | UTC
RCT: Weaning of maintenance immunosuppressive therapy in lupus nephritis.
23 Jun, 2022 | 10:18h | UTC
Cohort Study: Optimizing both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease.
23 Jun, 2022 | 10:01h | UTCOptimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary: Low-dose glucocorticoids show no negative impact on BMD – medwire News
Commentary on Twitter
New and important study on #glucocorticoids and bone health in inflammatory rheumatic diseases. https://t.co/6XakxJO37y doses <5 mg/d together with low disease activity seem to have a low risk for #osteoporosis pic.twitter.com/Na5eMHLMS3
— ARD & RMD Open (@ARD_BMJ) June 12, 2022
Cardiovascular disease in primary Sjögren’s syndrome: raising clinicians’ awareness.
22 Jun, 2022 | 10:55h | UTC
The clinician’s guide to prevention and treatment of osteoporosis.
20 Jun, 2022 | 01:22h | UTCThe clinician’s guide to prevention and treatment of osteoporosis – Osteoporosis International
RCT: Marine Omega-3 Fatty acid supplementation does not reduce the incidence of dry eye disease in healthy adults.
10 Jun, 2022 | 12:25h | UTCEfficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial – JAMA Ophthalmology (free for a limited period)
Invited Commentary: Another Disappointment for ω-3 Fatty Acid and Dry Eye Disease – JAMA Ophthalmology (free for a limited period)
Commentary on Twitter
In this randomized clinical trial, daily supplementation with marine omega-3 fatty acids (1 gram) for a median of 5.3 years had no significant effect on the incidence of diagnosed #dryeyedisease (DED) or reported DED symptoms. https://t.co/iTBONh6CZK
— JAMAOphthalmology (@JAMAOphth) June 9, 2022
NICE Guideline: Gout diagnosis and management.
9 Jun, 2022 | 11:35h | UTCGout: diagnosis and management – National Institute for Health and Care Excellence
M-A: Effects of diet on the outcomes of rheumatic and musculoskeletal diseases.
9 Jun, 2022 | 10:48h | UTCNews Release: Diet unlikely to ease progression of osteoarthritis, rheumatoid arthritis – BMJ